EVAX (Evaxion AS) Moat Score: 2/10 (As of Jun. 28, 2026)


EVAX Evaxion AS EVAX
22 GF Score
Price $3.23
! 2 Warning Signs
View Full Analysis

What is Evaxion AS Moat Score?

Evaxion AS EVAX -1.59% 22 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates EVAX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,402 Biotechnology companies, Evaxion AS ranks better than 58.06% on this metric.

Evaxion AS has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Evaxion AS has No Moat: Evaxion AS lacks significant market leadership and customer switching costs. The company operates in a competitive biotech space with limited brand strength and no clear cost advantages or regulatory barriers. Its intellectual property is not sufficiently strong to create a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Evaxion AS might have No Moat - Very weak/transient advantages.

Evaxion AS  (NAS:EVAX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Evaxion AS Moat Score Related Terms

EVAX vs DARE, LITS, TVGN: Moat Score Comparison

For the Biotechnology subindustry, Evaxion AS's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion AS Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion AS's Moat Score distribution charts can be found below:

* The bar in red indicates where Evaxion AS's Moat Score falls into.


EVAX
22GF Score
Evaxion AS EVAX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Evaxion AS (EVAX) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Evaxion AS ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Evaxion AS's Moat Score too high?
Evaxion AS's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Evaxion AS's value of 2 is 0% at this industry median. Based on the distribution chart, Evaxion AS ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Evaxion AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's Moat Score compare to DARE and LITS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #588 out of 1402 companies for Moat Score. This puts Evaxion AS in the upper half of its industry. The industry median Moat Score is 2.00. Evaxion AS's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evaxion AS's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evaxion AS's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Evaxion AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Evaxion AS (EVAX), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
22GF Score

Get the complete analysis for EVAX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.23
Price